- Report
- February 2025
- 315 Pages
Global
From €4368EUR$4,799USD£3,710GBP
- Report
- January 2025
- 456 Pages
Global
From €4505EUR$4,950USD£3,827GBP
- Report
- April 2025
- 370 Pages
Global
From €5324EUR$5,850USD£4,522GBP
- Report
- April 2025
- 92 Pages
Global
From €5324EUR$5,850USD£4,522GBP
- Report
- April 2025
- 70 Pages
Global
From €5324EUR$5,850USD£4,522GBP
- Report
- February 2025
- 200 Pages
Global
From €4087EUR$4,490USD£3,471GBP
- Report
- November 2021
- 261 Pages
Global
From €2389EUR$2,625USD£2,029GBP
€4778EUR$5,250USD£4,059GBP
- Report
- April 2024
- 183 Pages
Global
From €4096EUR$4,500USD£3,479GBP
- Report
- January 2024
- 200 Pages
Global
From €3777EUR$4,150USD£3,208GBP
- Report
- July 2022
- 176 Pages
Global
From €2202EUR$2,419USD£1,870GBP
€3146EUR$3,456USD£2,672GBP
- Book
- April 2020
- 272 Pages
- Book
- August 2021
- 312 Pages
- Book
- February 2024
- 640 Pages
- Book
- September 2023
- 288 Pages
- Book
- September 2023
- 288 Pages
- Book
- April 2019
- 816 Pages
- Book
- July 2018
- 832 Pages
- Book
- October 2015
- 520 Pages

Hepatocellular Carcinoma (HCC) is a type of cancer that originates in the liver. It is the most common form of liver cancer and is the third leading cause of cancer-related deaths worldwide. HCC is typically diagnosed in individuals with underlying liver diseases such as cirrhosis, hepatitis B or C, and non-alcoholic fatty liver disease. Treatment options for HCC include surgery, radiation therapy, chemotherapy, and targeted therapy.
The oncology market for HCC is highly competitive, with a number of companies offering treatments and therapies. These include AbbVie, Bristol-Myers Squibb, Merck, Novartis, Pfizer, Roche, and Takeda. Additionally, there are a number of smaller companies that are developing novel therapies for HCC, such as Aduro Biotech, ArQule, and Oncoceutics. Show Less Read more